Effects of Diabetes Mellitus on Cognitive Decline in Patients with Alzheimer Disease: A Systematic Review

Canadian Journal of Diabetes

Volumn 41, Issue 1, 2017, Pages 114-119

  Li, Jun ^a,b   Cesari, Matteo ^b   Liu, Fei ^a   Dong, Birong ^a   Vellas, Bruno ^b  

^a SICHUAN UNIVERSITY   (China)

^b UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

Alzheimer disease; cognitive decline; cognitive function; diabetes mellitus; systematic review

Indexed keywords

ALZHEIMER DISEASE; COGNITION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; EVIDENCE BASED PRACTICE; HUMAN; MEDICAL HISTORY; MENTAL DETERIORATION; REVIEW; SYSTEMATIC REVIEW; COGNITIVE DYSFUNCTION; FACTUAL DATABASE; PSYCHOLOGY; RISK FACTOR; TRENDS;

ALZHEIMER DISEASE; COGNITIVE DYSFUNCTION; DATABASES, FACTUAL; DIABETES MELLITUS; DISEASE PROGRESSION; HUMANS; RISK FACTORS;

EID: 84995404164     PISSN: 14992671     EISSN: 23523840     Source Type: Journal    
DOI: 10.1016/j.jcjd.2016.07.003     Document Type: Review

References (49)

1. 1 Prince, M., Bryce, R., Albanese, E., et al. The global prevalence of dementia: A systematic review and metaanalysis. Alzheimers Dement 9 (2013), 63–75.
2. 2 Ballard, C., Gauthier, S., Corbett, A., et al. Alzheimer's disease. Lancet 377 (2011), 1019–1031.
3. 3 Downs, C.A., Faulkner, M.S., Toxic stress, inflammation and symptomatology of chronic complications in diabetes. World J Diabetes 6 (2015), 554–565.
4. 4 Alzheimer's Association, 10: Older adults. Diabetes Care 39:Suppl. 1 (2016), S81–5.
5. 5 Akomolafe, A., Beiser, A., Meigs, J.B., et al. Diabetes mellitus and risk of developing Alzheimer disease: Results from the Framingham Study. Arch Neurol 63 (2006), 1551–1555.
6. 6 Yaffe, K., Falvey, C., Hamilton, N., et al. Diabetes, glucose control, and 9-year cognitive decline among older adults without dementia. Arch Neurol 69 (2012), 1170–1175.
7. 7 Roberts, R.O., Knopman, D.S., Geda, Y.E., et al. Association of diabetes with amnestic and nonamnestic mild cognitive impairment. Alzheimers Dement 10 (2014), 18–26.
8. 8 Cukierman, T., Gerstein, H.C., Williamson, J.D., Cognitive decline and dementia in diabetes: Systematic overview of prospective observational studies. Diabetologia 48 (2005), 2460–2469.
9. 9 Craft, S., Alzheimer disease: Insulin resistance and AD: Extending the translational path. Nat Rev Neurol 8 (2012), 360–362.
10. 10 Lesort, M., Johnson, G.V., Insulin-like growth factor-1 and insulin mediate transient site-selective increases in tau phosphorylation in primary cortical neurons. Neuroscience 99 (2000), 305–316.
11. 11 Takeda, S., Sato, N., Rakugi, H., Morishita, R., Molecular mechanisms linking diabetes mellitus and Alzheimer disease: Beta-amyloid peptide, insulin signaling, and neuronal function. Mol Biosyst 7 (2011), 1822–1827.
12. 12 Ascher-Svanum, H., Chen, Y.F., Hake, A., et al. Cognitive and functional decline in patients with mild Alzheimer dementia with or without comorbid diabetes. Clin Ther 37 (2015), 1195–1205.
13. 13 Dominguez, R.O., Marschoff, E.R., Gonzalez, S.E., et al. Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients. Diabetes Res Clin Pract 98 (2012), 68–74.
14. 14 Helzner, E.P., Luchsinger, J.A., Scarmeas, N., et al. Contribution of vascular risk factors to the progression in Alzheimer disease. Arch Neurol 66 (2009), 343–348.
15. 15 Li, J., Zhang, M., Xu, Z.Q., et al. Vascular risk aggravates the progression of Alzheimer's disease in a Chinese cohort. J Alzheimers Dis 20 (2010), 491–500.
16. 16 McKhann, G., Drachman, D., Folstein, M., et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984), 939–944.
17. 17 Bhargava, D., Weiner, M.F., Hynan, L.S., et al. Vascular disease and risk factors, rate of progression, and survival in Alzheimer's disease. J Geriatr Psychiatry Neurol 19 (2006), 78–82.
18. 18 Mielke, M.M., Rosenberg, P.B., Tschanz, J., et al. Vascular factors predict rate of progression in Alzheimer disease. Neurology 69 (2007), 1850–1858.
19. 19 Musicco, M., Palmer, K., Salamone, G., et al. Predictors of progression of cognitive decline in Alzheimer's disease: The role of vascular and sociodemographic factors. J Neurol 256 (2009), 1288–1295.
20. 20 Regan, C., Katona, C., Walker, Z., et al. Relationship of vascular risk to the progression of Alzheimer disease. Neurology 67 (2006), 1357–1362.
21. 21 Sakurai, H., Hanyu, H., Sato, T., et al. Vascular risk factors and progression in Alzheimer's disease. Geriatr Gerontol Int 11 (2011), 211–214.
22. 22 Sanz, C., Andrieu, S., Sinclair, A., et al. Diabetes is associated with a slower rate of cognitive decline in Alzheimer disease. Neurology 73 (2009), 1359–1366.
23. 23 de la Monte, S.M., Wands, J.R., Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol 2 (2008), 1101–1113.
24. 24 Abellan van Kan, G., Rolland, Y., Nourhashemi, F., et al. Cardiovascular disease risk factors and progression of Alzheimer's disease. Dement Geriatr Cogn Disord 27 (2009), 240–246.
25. 25 Folstein, M.F., Folstein, S.E., McHugh, P.R., “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975), 189–198.
26. 26 Tsoi, K.K., Chan, J.Y., Hirai, H.W., et al. Cognitive tests to detect dementia: A systematic review and meta-analysis. JAMA Intern Med 175 (2015), 1450–1458.
27. 27 Gregg, E.W., Yaffe, K., Cauley, J.A., et al. Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group. Arch Intern Med 160 (2000), 174–180.
28. 28 Haan, M.N., Shemanski, L., Jagust, W.J., et al. The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA 282 (1999), 40–46.
29. 29 Arevalo-Rodriguez, I., Smailagic, N., Roque, I.F.M., et al. Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev(3), 2015 CD010783.
30. 30 Thabit, H., Kyaw Tun, T., McDermott, J., Sreenan, S., Executive function and diabetes mellitus: A stone left unturned?. Curr Diabetes Rev 8 (2012), 109–115.
31. 31 Pineda Cuenca, M., Custardoy Olavarrieta, J., Ortin Arroniz, J.M., et al. [Degree of understanding, treatment and control of hypertension, hypercholesterolemia and diabetes mellitus in the general adult population]. Aten Primaria 33 (2004), 254–260.
32. 32 Kuller, L.H., Lopez, O.L., Jagust, W.J., et al. Determinants of vascular dementia in the Cardiovascular Health Cognition Study. Neurology 64 (2005), 1548–1552.
33. 33 Beeri, M.S., Silverman, J.M., Davis, K.L., et al. Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology. J Gerontol A Biol Sci Med Sci 60 (2005), 471–475.
34. 34 Heitner, J., Dickson, D., Diabetics do not have increased Alzheimer-type pathology compared with age-matched control subjects: A retrospective postmortem immunocytochemical and histofluorescent study. Neurology 49 (1997), 1306–1311.
35. 35 Vlassara, H., Intervening in atherogenesis: Lessons from diabetes. Hosp Pract 35 (2000), 25–27 32, 5–9.
36. 36 Holscher, C., First clinical data of the neuroprotective effects of nasal insulin application in patients with Alzheimer's disease. Alzheimers Dement 10:Suppl. 1 (2014), S33–7.
37. 37 Cheng, C., Lin, C.H., Tsai, Y.W., et al. Type 2 diabetes and antidiabetic medications in relation to dementia diagnosis. J Gerontol A Biol Sci Med Sci 69 (2014), 1299–1305.
38. 38 Hsu, C.C., Wahlqvist, M.L., Lee, M.S., Tsai, H.N., Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. J Alzheimers Dis 24 (2011), 485–493.
39. 39 Gupta, A., Bisht, B., Dey, C.S., Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. Neuropharmacology 60 (2011), 910–920.
40. 40 Kickstein, E., Krauss, S., Thornhill, P., et al. Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc Natl Acad Sci U S A 107 (2010), 21830–21835.
41. 41 Egefjord, L., Gejl, M., Moller, A., et al. Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer's disease: Protocol for a controlled, randomized double-blinded trial. Dan Med J, 59, 2012 A4519.
42. 42 McClean, P.L., Holscher, C., Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease. Neuropharmacology 76:Pt A (2014), 57–67.
43. 43 Baraka, A., ElGhotny, S., Study of the effect of inhibiting galanin in Alzheimer's disease induced in rats. Eur J Pharmacol 641 (2010), 123–127.
44. 44 Francis, G.J., Martinez, J.A., Liu, W.Q., et al. Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy. Brain 131:Pt 12 (2008), 3311–3334.
45. 45 Craft, S., Baker, L.D., Montine, T.J., et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: A pilot clinical trial. Arch Neurol 69 (2012), 29–38.
46. 46 Coley, N., Andrieu, S., Gardette, V., et al. Dementia prevention: Methodological explanations for inconsistent results. Epidemiol Rev 30 (2008), 35–66.
47. 47 Arvanitakis, Z., Schneider, J.A., Wilson, R.S., et al. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology 70:19 Pt 2 (2008), 1795–1802.
48. 48 Cramer, C., Haan, M.N., Galea, S., et al. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 71 (2008), 344–350.
49. 49 Zandi, P.P., Anthony, J.C., Hayden, K.M., et al. Reduced incidence of AD with NSAID but not H2 receptor antagonists: The Cache County Study. Neurology 59 (2002), 880–886.